Replacing warfarin with a novel oral anticoagulant: Risk of recurrent bleeding and stroke in patients with warfarin ineligible or failure in patients with atrial fibrillation (The ROAR study)
ConclusionIn WI patients rechallenged with DOACs, a significant proportion developed repeat MBE. LAAO devices seem reasonable in those patients who undergo major interventions to manage MBE with cautious and temporary continuation of DOAC.
Source: Journal of Cardiovascular Electrophysiology - Category: Cardiology Authors: Mohit K. Turagam, Valay Parikh, Muhammad R. Afzal, Rakesh Gopinathannair, Madhav Lavu, Arun Kanmanthareddy, Jayasree Pillarisetti, Madhu Reddy, Donita Atkins, Sudharani Bommana, Melissa Jaeger, Courtney Jeffery, Sanghamitra Mohanty, Pasquale Santangeli, J Tags: ORIGINAL ARTICLE Source Type: research
More News: Atrial Fibrillation | Bleeding | Cardiology | Cardiovascular | Coumadin | Gastroenterology | Heart | Stroke | Study | Thrombosis | Warfarin